BridgeBio Pharma Inc vs Lamb Weston Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Lamb Weston Holdings Inc trades at $52.79 (market cap $7.12B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LW | |
|---|---|---|
Market Cap | $16.61B | $7.12B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $66.57 |
52-Week Low | $47.29 | $38.48 |
Enterprise Value | $18.16B | $11.00B |
Dividend Yield | — | 2.93% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →